Skip to main content
SpringerLink
Log in

Galanthamine in Alzheimer’s Disease

A New Alternative to Tacrine?

  • Leading Article
  • Published:
CNS Drugs Aims and scope Submit manuscript

Summary

Galanthamine (galantamine), a tertiary alkaloid derived from the bulbs of the snowdrop and various Narcissus species, is a selective, centrally active and reversible inhibitor of acetylcholinesterase that is suitable for oral therapy. After a long period during which the investigational and clinical use of the drug was limited to anaesthesia and the treatment of peripheral paralysis syndromes in Eastern Europe, the molecule has now emerged as a promising lead substance for the treatment of cognitive decline in Alzheimer’s disease.

Galanthamine has similar therapeutic potential to tacrine, but has a significantly more favourable pharmacokinetic and toxicity profile. A chemical synthesis process on the required industrial scale of several tons per year has become available, removing a major obstacle to the development of the drug. Clinical trials published so far are, however, rather limited in terms of both design and patient number. The main reason for this is that there has been a lack of strong support for the drug within the pharmaceutical industry. However, the available data support the notion that this molecule, if properly developed, could be a peer for any second-generation cholinergic drug currently in clinical trials for the symptomatic treatment of Alzheimer’s disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fales HM, Giuffrida LD, Wildman WC. Alkaloids of the Amaryllidaceae VIII The structures of narcissamine, leucorine, pseudoleucorine and methlpseudoleucorine. J Am Chem Soc 1956; 78: 4145

    Article  CAS  Google Scholar 

  2. Proskurnina NF, Yakovleva J. Alkaloids of Galanthus worownii. J Gen Chem USSR 1952; 22: 1899–902

    CAS  Google Scholar 

  3. Uyeo S, Kobayashi S. Pharm Bull Tokyo 1953; 1: 139

    Article  CAS  Google Scholar 

  4. Boissier JR, Combes G, Pagny J. La galanthamine, puissant cholinergique naturel. Ann Pharm Fr 1960; 48: 888–900

    Google Scholar 

  5. Irwin RL, Smith HJ. Cholinesterase inhibition by galanthamine and lycoramine. Biochem Pharmacol 1960; 3: 147–8

    Article  PubMed  CAS  Google Scholar 

  6. Nesterenko LN. Influence exerted by galanthamine on the acetylcholinesterase activity of various regions of the brain. Farmakol Toksikol 1964; 28: 413–4

    Google Scholar 

  7. Pestel M. Une nouvelle médication de la myasthenie et des dystrophies neuro-musculaires: la nivaline. Presse Med 1961; 69: 182–3

    PubMed  CAS  Google Scholar 

  8. Revelli U, Grasso E. Le traitement de la poliomyelite a la nivaline. Minerva Med 1962; 53: 881–4

    PubMed  CAS  Google Scholar 

  9. Kilimov N. Trattamento della neuralgia del nervo trigemino. Cultura Medica 1961; 23: 313–22

    Google Scholar 

  10. Tsukanova VN. Galanthamine in the treatment of patients with cochlear neuritis and ganglionitis [in Russian]. Vestn Otorinolaringol 1967; 29(3): 57–60

    PubMed  CAS  Google Scholar 

  11. Stojanov EA. Clinical experiences with the new curare antidote galanthamine (nivalin). In: Mayrhofer O, editor. European trends in anaesthesiology: international anaesthesiology clinics. Boston: Brown & Co., 1965: 675–85

    Google Scholar 

  12. Cozanitis DA. Experiences with galanthamine hydrobromide as curare antagonist. Anaesthesia 1971; 20(6): 226–9

    CAS  Google Scholar 

  13. Sedloev S, Georgiev I, Milev M. On the effect of Nivalin upon intestinal peristalsis. Acta Med (Sofia) 1964; 43(1): 69–73

    CAS  Google Scholar 

  14. Cozanitis DA, Nuuttila K, Karhunen P, et al. Changes in cardiac rhythm with galanthamine hydrobromide. Anaesthesia 1973; 22: 457–9

    CAS  Google Scholar 

  15. Cozanitis DA, Toivakka E, Dessypris A. Electroencephalographic and blood chemistry responses to galanthamine hydrobromide in epileptic volunteers. Anaesthesia 1973; 22: 31–3

    CAS  Google Scholar 

  16. Cozanitis DA. Galanthamine hydrobromide versus neostigmine. Anaesthesia 1974; 29: 123–68

    Article  Google Scholar 

  17. Cozanitis DA, Toivakka E. Study of galanthamine hydrobromide and atropine/neostigmine. Anaesthesia 1971; 20(11): 416–21

    CAS  Google Scholar 

  18. Holl G, Straschill M, Thomsen T, et al. Effect of the cholinesterase inhibiting substance galanthamine on human EEG and visual evoked potentials. Electroencephalogr Clin Neurophysiol 1992; 82: 445–52

    Article  PubMed  CAS  Google Scholar 

  19. Riemann D, Gann H, Dressing H, et al. Influence of the cholinesterase inhibitor galanthamine hydrobromide on normal sleep. Psychiatry Res 1994; 51: 253–67

    Article  PubMed  CAS  Google Scholar 

  20. Tassonyi E, Labancz K, Vimláti L, et al. Postoperative apnoea following nivalin administration. Anaesthesia 1976; 25: 529–31

    CAS  Google Scholar 

  21. Cozanitis DA, Toivakka E. Treatment of respiratory depression with the anticholinesterase drug galanthamine hydrobromide. Anaesthesia 1974; 29: 581–4

    Article  PubMed  CAS  Google Scholar 

  22. Losev NA, Kamenetskii VK. Method of treating parkinsonism with metamizil in combination with galanthamine (clinico-experimental basis). Zh Nevropatol Psikhiatr 1985; 85(3): 376–81

    PubMed  CAS  Google Scholar 

  23. Becker RE, Moriearty P, Unni L. The second generation of cholinesterase inhibitors: clinical and pharmacological effects. In: Becker R, Giacobini E, editors. Cholinergic basis for Alzheimer therapy. Boston: Birkhauser, 1991: 263–96

    Google Scholar 

  24. Rainer M, Mucke H, Janoch P, et al. Galanthamine treatment in Alzheimer’s disease: the identification of responders. Neu-ropsychopharmacology 1994; 10 No. 3, Pt 2: 2155

    Google Scholar 

  25. Giacobini E. The second generation of cholinesterase inhibitors: pharmacological aspects. In: Becker R, Giacobini E, editors. Cholinergic basis for Alzheimer’s therapy. Boston: Birkhauser, 1991: 247–62

    Google Scholar 

  26. Bickel U, Thomsen T, Weber W et al. Pharmacokinetics of galanthamine in humans and corresponding cholinesterase inhibition. Clin Pharmacol Ther 1991; 50: 420–8

    Article  PubMed  CAS  Google Scholar 

  27. Mihailova D, Yamboliev I, Dishovski C. Modeling of pharmacokinetic and pharmacodynamic behaviour of nivalin in anaesthetized cats. Methods Find Exp Clin Pharmacol 1985; 7(11): 595–601

    PubMed  CAS  Google Scholar 

  28. Westra P, Van Thiel MJS, Vermeer GA, et al. Pharmacokinetics of galanthamine (a long-acting anticholinesterase drug) in anaesthetized patients. Br J Anaesth 1986; 58: 1303–7

    Article  PubMed  CAS  Google Scholar 

  29. Mihailova D, Velkov M, Zhivkova Z. In vitro metabolism of galanthamine hydrobromide (Nivalin) by rat and rabbit liver homogenate. Eur J Drug Metab Pharmacokinet 1987; 12(1): 25–30

    Article  PubMed  CAS  Google Scholar 

  30. Bickel U, Thomsen T, Fischer JP, et al. Galanthamine: pharmacokinetics, tissue distribution and cholinesterase inhibition in brain of mice. Neuropharmacology 1991; 30(5): 447–54

    Article  PubMed  CAS  Google Scholar 

  31. Thomsen T, Bickel U, Fischer JP, et al. Stereoselectivity of cholinesterase inhibition by galanthamine and tolerance in humans. Eur J Clin Pharmacol 1990; 39: 603–5

    Article  PubMed  CAS  Google Scholar 

  32. Berzewski H, Kewitz H, Davis B, et al. Galanthamine, a selective nontoxic centrally acting and reversible acetylcholines-terase inhibitor, for the treatment of SDAT [abstract]. XIXth Collegium Internationale Neuro-Psychopharmacologicum Congress: 1994 Jun 27–Jul 1; Washington, DC. Neuropsycho-pharmacology 1994; 10(35; Pt 2): P–58–147

    Google Scholar 

  33. Mihailova D, Yamboliev I. Pharmacokinetics of galanthamine hydrobromide (Nivalin) following single intravenous and oral administration in rats. Pharmacology 1986; 32(6): 301–6

    Article  PubMed  CAS  Google Scholar 

  34. Thomsen T, Kaden B, Fischer JP, et al. Inhibition of acetylcholinesterase activity in human brain tissue and erythrocytes by galanthamine, physostigmine and tacrine. Eur J Clin Chem Clin Biochem 1991; 29: 487–92

    PubMed  CAS  Google Scholar 

  35. Pleul O, Rost L, Thomsen T, et al. Correlation between blood and tissue levels of tetrahydroaminoacridine, cholinesterase inhibition, and acetylcholine increase in the brain. In: Kewitz H, Thomsen T, Bickel U, editors. Pharmacological interventions on central cholinergic mechanisms in senile dementia (Alzheimer’s disease). München: W. Zuckschwerdt, 1989: 292–7

    Google Scholar 

  36. Thomsen T, Kewitz H. Selective inhibition of human acetylcho-linesterase by galanthamine in vitro and in vivo. Life Sci 1990; 46: 1553–8

    Article  PubMed  CAS  Google Scholar 

  37. Thomsen T, Zendeh B, Fischer JP, et al. In vitro effects of various cholinesterase inhibitors on acetyl- and butyrylcholin-esterase of healthy volunteers. Biochem Pharmacol 1991; 41(1): 139–41

    Article  PubMed  CAS  Google Scholar 

  38. Cooper JR, Bloom FE, Roth RH. The biochemical basis of neuropharmacology. 5th ed. New York: Oxford University Press, 1986

    Google Scholar 

  39. Becker RE, Colliver J, Elble R, et al. Effects of metrifonate, a long-acting cholinesterase inhibitor, in Alzheimer disease: report of an open trial. Drug Dev Res 1990; 19: 425–34

    Article  Google Scholar 

  40. Ravindran RS, Cummins DF, Pantazis KL. Unusual aspects of low levels of pseudocholinesterase in a pregnant patient. Anaesth Analg 1982; 61: 953–7

    CAS  Google Scholar 

  41. Wagstaff AJ, McTavish D. Tacrine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer’s disease. Drugs Aging 1994; 4(6): 510–40

    Article  PubMed  CAS  Google Scholar 

  42. Watkins PB, Zimmerman HJ, Knapp MJ, et al. Hepatotoxic effects of tacrine administration in patients with Alzheimer’s disease. JAMA 1994; 271(13): 992–8

    Article  PubMed  CAS  Google Scholar 

  43. Knapp MJ, Gracon SI, Davis CS, et al. Efficacy and safety of high-dose tacrine: a 30-week evaluation. Alzheimer Dis Assoc Disord 1994; 8 Suppl. 2: S22–31

    Google Scholar 

  44. Davis B. Method of treating Alzheimer’s disease. US Patent 4 663 318 (1987 May 5)

  45. Thomsen T, Kewitz H. Galanthamine treatment in senile dementia of Alzheimer’s type: a case report. In: Kewitz H, Thomsen T, Bickel U, editors. Pharmacological interventions on central cholinergic mechanisms in senile dementia (Alzheimer’s disease). München: W. Zuckschwerdt, 1989: 238–41

    Google Scholar 

  46. Sweeney JE, Höhmann CF, Moran TH, et al. A long-acting cholinesterase inhibitor reverses spatial memory deficits in mice. Pharmacol Biochem Behav 1988; 31(1): 141–7

    Article  PubMed  CAS  Google Scholar 

  47. Chaplygina SR, Il’iuchenok RLU. Effect of cholinergic substances in experimental amnesia [in Russian]. Zh Vyssh Nerv Deiat Im Pav 1976; 26: 1091–3

    CAS  Google Scholar 

  48. Rainer M, Mark T, Haushofer A. Galanthamine hydrobromide in the treatment of senile dementia of Alzheimer’s type. In: Kewitz H, Thomsen T, Bickel U, editors. Pharmacological interventions on central cholinergic mechanisms in senile dementia (Alzheimer’s disease). München: W. Zuckschwerdt, 1989: 233–7

    Google Scholar 

  49. Dal-Bianco P, Maly J, Wober C, et al. Galanthamine treatment in Alzheimer’s disease. J Neural Transm 1991; Suppl. 33: 59-63

  50. Wilcock GK, Scott M, Pearsall T, et al. Galanthamine and the treatment of Alzheimer’s disease. Int J Geriatr Psychiatr 1993; 8(9): 781–2

    Google Scholar 

  51. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed, rev. Washington, DC: American Psychiatry Association, 1987

  52. Wilcock G, Wilkinson D. Galanthamine hydrobromide — interim results of a group comparative, placebo controlled study of efficacy and safety in patients with a diagnosis of senile dementia of the Alzheimer’s type [abstract]. 5th International Conference on Alzheimer’s Disease and Related Disorders: 1996 Jul; Osaka, abstract no. 578. Neurobiol Aging 1996; Suppl. Vol. 17 No. 4S: 144

    Google Scholar 

  53. Rainer M, Mucke H. Long-term efficacy of galanthamine in Alzheimer’s disease: cognitive parameters after two and three years of treatment [abstract]. 8th Congress of the Association of European Psychiatrists: 1996 Jul 8–12; London

    Google Scholar 

  54. Knapp MJ, Knopman DS, Solomon PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer’s disease. JAMA 1994; 271(13): 985–91

    Article  PubMed  CAS  Google Scholar 

  55. McPherson S. Galanthamine: the new treatment of choice in Alzheimer’s disease?. Inpharma 1995; Sep 2 (1002): 3-5

  56. Barton DHR, Kirby GW. The synthesis of galanthamine. Proc Chem Soc 1960: 392-3

Download references

Author information

Authors and Affiliations

  1. Psychiatric Department and Memory Clinic, Donauspital im Sozialmedizinischen Zentrum Ost, Langobardenstrasse 122, A-1220, Vienna, Austria

    Michael Rainer

Authors
  1. Michael Rainer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rainer, M. Galanthamine in Alzheimer’s Disease. CNS Drugs 7, 89–97 (1997). https://doi.org/10.2165/00023210-199707020-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-199707020-00001

Keywords

Search

Navigation